PDCD1 and neoplasm: This study provides robust evidence that ICGA-A, a bioactive compound derived from Taraxacum officinale, significantly enhance the efficacy of PD-1/PD-L1 inhibitor 2 by modulating the tumor microenvironment (TME) in TNBC.